Jetema: Q1 2026 Consolidated Revenue KRW 16B, Operating Loss Widens, Domestic Toxin Launch and Global Clinical Progress
Q1 2026 consolidated revenue KRW 16.0B (similar to Q1 2025: KRW 15.8B), operating loss KRW 0.67B (Q1 2025 loss KRW 0.14B), controlling interest net loss KRW 2.13B (improved from Q1 2025 loss KRW 3.66B)
Dec 2024: Domestic product approval for JETEMA THE TOXIN 100U; Mar 2025: domestic launch; Dec 2025: US phase 2 clinical completed; China phase 3 ongoing
Global license-out deals: China Huadong (USD 459M), Brazil (USD 121M), Turkey (USD 60M), Thailand (USD 32M) etc.
End-Q1 2026: Debt ratio 196% (down from 222% at end-2025), net debt ratio 158% (down from 180%)
Dec 2024: 100% stock dividend (funded by share premium)
R&D expense KRW 2.66B (16.6% of revenue), development of new pipelines including Type A 150kDa and Type E
Administrative litigation over Pharmaceutical Affairs Act violation: partial win in first trial, appeal ongoing (execution suspended)
Key subsidiaries: JETEMA USA (assets KRW 19.1B, net loss KRW 0.54B), Shanghai entity, total 5 consolidated entities